Latest total revenue for TCON: $3.2M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2024
Trailing 12 months ending Jun 2024
TRACON Pharmaceuticals (TCON) currently reports a total revenue of $3.2M as of June 2024. That compares with $9M in the prior-year period — down 64.4% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore TRACON Pharmaceuticals's total revenue history and peer comparisons.
TRACON Pharmaceuticals's total revenue decreased from $9M to $3.2M — a 64.4% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
TRACON Pharmaceuticals's total revenue of $3.2M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
TRACON Pharmaceuticals reported $3.2M in total revenue as of June 2024. That compares with $9M in the prior-year period — down 64.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $3.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for TRACON Pharmaceuticals, and consider following TCON for alerts when major investors trade the stock.